Effectiveness of Pegcetacoplan, Avacincaptad Pegol in Geographic Atrophy Treatment | ASRS 2023
Paul Hahn, M.D., Ph.D., vitreoretinal surgeon at NJRetina, chatted with MHE about the latest geographic atrophy treatments and shared key takeaways found from clinical trials examining them. Hahn presented on macular degeneration today at the American Society of Retina Specialists annual meeting in Seattle.
Paul Hahn, M.D., Ph.D., vitreoretinal surgeon at NJRetina, chatted with MHE about the latest geographic atrophy treatments and shared key takeaways found from clinical trials examining them. Hahn presented on macular degeneration today at the American Society of Retina Specialists annual meeting in Seattle.
When asked on the timing these treatments should be affecting the chronic disease, Hahn shared the primary endpoints were found in clinical trials at one year's time. However, in his team's clinical trials they have data spanning out to two years.
"In those trials, we interestingly appear to observe an increasing benefit over time," Hahn said. "You know, the the reasons for this are still not understood, but we hypothesize that maybe there's a cumulative effect of ongoing therapy. Those trends still need to be explored, but I think in a chronic disease, this is something that's going to show benefit, hopefully over a lifetime.. we're not looking for immediate results, but really long term results."
Changes to Susvimo Port Delivery System Explained | ASRS 2024
July 22nd 2024Dante J. Pieramici, M.D., of the California Retina Research Foundation, explains changes made to the Susvimo port delivery system that are designed. to prevent the septum dislodgment that led to Genentech pulling the product off the market.
Read More
Results from retrospective real-world studies presented at American Society of Retina Specialists annual meetiing put the risk of retinal vasculitis from Syfovre at 1 in 1,330 patients. But other results presented at the meeting supplied evidence that Syfovre fends off vision loss caused by geographic atrophy, an advanced form of dry age-related macular degeneration.
Read More
